Geode Capital Management’s Nuvectra Corporation Common Stock NVTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-150,502
Closed -$204K 4272
2019
Q3
$204K Sell
150,502
-1,928
-1% -$3.78K ﹤0.01% 3759
2019
Q2
$510K Sell
152,430
-57,480
-27% -$364K ﹤0.01% 3459
2019
Q1
$2.31M Buy
209,910
+9,249
+5% +$125K ﹤0.01% 2777
2018
Q4
$3.28M Buy
200,661
+64,249
+47% +$1.23M ﹤0.01% 2485
2018
Q3
$3M Buy
136,412
+13,997
+11% +$269K ﹤0.01% 2667
2018
Q2
$2.51M Buy
122,415
+67,968
+125% +$1.15M ﹤0.01% 2724
2018
Q1
$708K Hold
54,447
﹤0.01% 3279
2017
Q4
$422K Hold
54,447
﹤0.01% 3422
2017
Q3
$721K Buy
54,447
+3,499
+7% +$41.4K ﹤0.01% 3235
2017
Q2
$676K Hold
50,948
﹤0.01% 3255
2017
Q1
$347K Hold
50,948
﹤0.01% 3456
2016
Q4
$256K Hold
50,948
﹤0.01% 3524
2016
Q3
$352K Hold
50,948
﹤0.01% 3388
2016
Q2
$377K Sell
50,948
-4,194
-8% -$33.4K ﹤0.01% 3337
2016
Q1
$298 Buy
+55,142
New +$297K ﹤0.01% 3483

Other funds holding NVTR

Geode Capital Management's NVTR Position: Q4 2019 in Review

Geode Capital Management sold out of Nuvectra Corporation Common Stock (NVTR) in Q4 2019, closing a stake of 150,502 shares — an estimated $204K sold.

Geode Capital Management first reported a position in NVTR in Q1 2016 and held it in 15 quarters. The position peaked at $3.28M in Q4 2018. 7 funds tracked by Wall St. Rank hold NVTR as of Q4 2019.

  • Geode Capital Management reported no remaining Nuvectra Corporation Common Stock position as of Q4 2019 after selling out during the quarter.
  • Geode Capital Management sold 150,502 Nuvectra Corporation Common Stock shares in Q4 2019, an estimated $204K.
  • Geode Capital Management first reported a position in Nuvectra Corporation Common Stock in Q1 2016 and held it in 15 quarters.
  • Geode Capital Management's Nuvectra Corporation Common Stock position peaked at $3.28M in Q4 2018.
  • 7 funds tracked by Wall St. Rank held Nuvectra Corporation Common Stock as of Q4 2019.

Based on Geode Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.